Ubs Group Ag Novo Cure LTD Call Options Transaction History

Ubs Group Ag

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$15.61 - $23.34 $1.06 Million - $1.58 Million	-67,627 Reduced 25.27%	200,000 $3.13 Million
Q2 2024 Aug 13, 2024	BUY	$11.83 - $24.05 $3.17 Million - $6.44 Million	267,627 New	267,627 $4.58 Million
Q4 2023 Feb 09, 2024	SELL	$11.13 - $15.78 $32,277 - $45,762	-2,900 Reduced 6.99%	38,600 $576,000
Q2 2023 Aug 11, 2023	SELL	$40.29 - $82.51 $1.04 Million - $2.12 Million	-25,700 Reduced 38.24%	41,500 $1.72 Million
Q1 2023 May 12, 2023	BUY	$56.44 - $118.81 $1.52 Million - $3.2 Million	26,900 Added 66.75%	67,200 $4.04 Million
Q4 2022 Feb 08, 2023	BUY	$63.98 - $85.37 $2.1 Million - $2.81 Million	32,900 Added 444.59%	40,300 $2.96 Million
Q3 2021 Nov 15, 2021	SELL	$116.17 - $194.55 $2.04 Million - $3.42 Million	-17,600 Reduced 70.4%	7,400 $860,000
Q2 2021 Aug 13, 2021	BUY	$130.4 - $225.58 $834,560 - $1.44 Million	6,400 Added 34.41%	25,000 $5.55 Million
Q3 2019 Nov 14, 2019	SELL	$61.86 - $97.8 $1.94 Million - $3.07 Million	-31,400 Reduced 62.8%	18,600 $1.39 Million
Q2 2018 Aug 14, 2018	SELL	$19.85 - $32.0 $496,250 - $800,000	-25,000 Reduced 33.33%	50,000 $1.57 Million
Q1 2017 Nov 14, 2017	BUY	N/A	75,000	75,000 $608,000

263

77M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $3.16B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.